MedTrace Logo

A Study of Artificial Intelligence ECG With ECG Devices to Detect Hypertrophic Cardiomyopathy Distinct From Athlete's

NCT06290570 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 183

Last updated 2026-03-19

No results posted yet for this study

Summary

The purpose of this study is to evaluate the AI-ECG algorithm for HCM in detecting HCM and in differentiating it from athlete's using not only the standard 12-lead ECG, but also ECGs obtained with the Apple Watch and Alivecor KardiaMobile devices.

Conditions

Interventions

DIAGNOSTIC_TEST

12-Lead ECG

A clinically performed 12-lead ECG tracing within 30 days of the appointment will be obtained from the subject medical record and will be used for AI-ECG analyses.

DIAGNOSTIC_TEST

Apple Smart Watch Single Lead ECG

A single lead ECG tracing will be collected using an Apple Smart Watch and tracing will be used for AI-ECG analyses.

DIAGNOSTIC_TEST

AliveCor KardiaMobile 6-Lead ECG

A 6-lead ECG tracing will be collected using an AliveCor KardiaMobile device and tracing will be used for AI-ECG analyses.

Sponsors & Collaborators

Principal Investigators

  • Konstantinos Siontis, MD · Mayo Clinic

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-07
Primary Completion
2025-06-25
Completion
2026-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06290570 on ClinicalTrials.gov